

MRC Toxicology Unit Masterclass Seminar

Understanding the Mechanism for Dose - Dependent Thrombocytopenia Associated with 2'MOE Antisense Oligonucleotides

When: 4pm BST Wednesday 22 September 2021

Where: [Join Zoom Meeting](#)
Meeting ID: 991 2124 5150
Passcode: pxAKuKDpg2

Dr Scott Henry

Senior Vice President
Ionis Pharmaceuticals

Seminar host: Dr Kirsti Hornigold



Biography:

Scott Henry, Ph.D., DABT – Received a Ph.D. in Biochemistry from North Dakota State University in 1991, studying the phosphorylation and regulation of the glycogen synthesis pathway in heart. Following his Ph.D., he was a post-doctoral fellow at Parke Davis in Ann Arbor Michigan in the department of toxicology until 1993. He then joined Ionis Pharmaceuticals, Inc. as a Senior Scientist in the department of toxicology. Along with a team of dedicated colleagues, he has characterized and studied the mechanisms of various toxicities that include the effects of oligonucleotide treatment on clotting time prolongation, alternative complement pathway activation, proinflammatory effects in rodents, platelet alterations and the effects related to the accumulation of oligonucleotide in kidney. Now as Vice President of Non-Clinical Development at Ionis he has participated in the development of approximately 8 different phosphorothioate oligodeoxynucleotides and over 30 different 2'-MOE modified phosphorothioate oligonucleotides.

Selected publications:

Slingsby MHL et al. *Haematologica*. 2021 Feb 11. doi: 10.3324/haematol.2020.260059. Epub ahead of print. PMID: 33567808.

Narayanan P et al. *Toxicol Sci*. 2018 Aug 1;164(2):613-626. doi: 10.1093/toxsci/kfy119. PMID: 29846725.

Henry SP et al. *Nucleic Acid Ther*. 2017 Aug;27(4):197-208. doi: 10.1089/nat.2017.0666. Epub 2017 May 25. PMID: 28541820.

Crooke ST et al. *Nucleic Acid Ther*. 2017;27(3):121-129. doi:10.1089/nat.2016.0650